Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by M101on Feb 10, 2021 8:52pm
102 Views
Post# 32533549

RE:The "science is great" - based on what??

RE:The "science is great" - based on what??Good question, because it made me think. I don't think it is great, yet, because it would have to prove out at least once to qualify.  But if it does then looking back we're all going say how great we knew it was.

I like the logic of the synthetic or math based approach, I like it a lot more than starting from some natural chemical that has demonstrated beneficial effect on a symptom likely to be several steps downstream of the root problem. Yes it's still just a hypothesis that pathologically misfolded oligomers are the root problem, but if validated then target selection based on the thermodynamics specific to the misfolding is elegantly logical. And then there's the synergy with the rapidly advancing field of biomarkers and the now obvious applicability to many other diseases. 

JMO



       

 

<< Previous
Bullboard Posts
Next >>